NextCure, Inc.(NXTC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 24 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NXTC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for NextCure, Inc. (NXTC), a Healthcare sector company. NXTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 24 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), NextCure, Inc. reports net income of $-9.8M, free cash flow of $-13.4M. Top institutional holders of NXTC by reported 13-F value include Squadron Capital Management, Affinity Asset Advisors,, Ikarian Capital,, based on the most recent SEC filings. NXTC trades on the Nasdaq exchange and files with the SEC under CIK 1661059. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NextCure, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-9.8M
Free Cash Flow
Q1 2026
$-13.4M
Get alerted when NXTC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NextCure, Inc. including:
Top Institutional Holders of NXTC
Squadron Capital Management LLC
$2.8M265,000 shAffinity Asset Advisors, LLC
$2.6M241,826 shIkarian Capital, LLC
$2.5M238,303 shSofinnova Ventures Inc
$2.4M222,654 shSILVERARC CAPITAL MANAGEMENT, LLC
$1.9M176,057 shPFIZER INC
$1.5M153,354 shOpaleye Management Inc.
$1.5M141,181 shAWM Investment Company, Inc.
$1.2M117,371 shExome Asset Management LLC
$1.2M115,500 shBOOTHBAY FUND MANAGEMENT, LLC
$743.5K69,617 sh
| Fund | Value | Shares |
|---|---|---|
| Squadron Capital Management LLC | $2.8M | 265,000 |
| Affinity Asset Advisors, LLC | $2.6M | 241,826 |
| Ikarian Capital, LLC | $2.5M | 238,303 |
| Sofinnova Ventures Inc | $2.4M | 222,654 |
| SILVERARC CAPITAL MANAGEMENT, LLC | $1.9M | 176,057 |
| PFIZER INC | $1.5M | 153,354 |
| Opaleye Management Inc. | $1.5M | 141,181 |
| AWM Investment Company, Inc. | $1.2M | 117,371 |
| Exome Asset Management LLC | $1.2M | 115,500 |
| BOOTHBAY FUND MANAGEMENT, LLC | $743.5K | 69,617 |
More Healthcare Companies
View all Healthcare →Put NXTC on your watchlist
Track score changes the day NextCure, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NXTC a good stock to buy?
13F Pro's AI-powered analysis of NextCure, Inc. (NXTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXTC are available on the NXTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NXTC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NextCure, Inc.'s investment landscape.